Group 1 - The company, Jiangsu Aidi Pharmaceutical Group Co., Ltd., plans to raise up to 185 million yuan through a simplified procedure to issue A-shares, primarily to acquire a 22.23% stake in its subsidiary, Nanjing Nanda Pharmaceutical Co., Ltd., for approximately 130 million yuan, and to supplement working capital with 55 million yuan [1] - Nanda Pharmaceutical specializes in thrombolytic drugs and low molecular weight heparin raw materials, making it one of the few integrated manufacturers in China holding production approvals for both raw materials and injectable formulations [2] - The acquisition of Nanda Pharmaceutical is expected to enhance the company's control over it, optimize financial performance, and maximize synergies, thereby strengthening its competitive position in the human protein sector [3] Group 2 - The stroke incidence in China is rising, with acute ischemic stroke cases projected to increase from 4.1 million in 2023 to 4.9 million by 2027, highlighting a significant unmet clinical need for effective stroke treatments [3] - The market for neuroprotective drugs in China is expected to grow from 11.5 billion yuan in 2024 to 16.9 billion yuan by 2030, and further to 26.2 billion yuan by 2035, indicating a strong demand for innovative stroke medications [3] - Aidi Pharmaceutical has maintained rapid growth in the HIV sector for three consecutive years, with the market for anti-HIV drugs in China estimated at 7 billion yuan in 2023, projected to exceed 11 billion yuan by 2027 [4] Group 3 - The company is advancing its core HIV pipeline and aims to establish a comprehensive commercialization system for new HIV drugs, addressing the significant challenge posed by the large population of HIV-infected individuals in China [4] - Aidi Pharmaceutical has made significant progress in its HIV drug pipeline, with new drugs like ACC017 and ADC118 entering clinical trials, and is also developing long-acting pre-exposure prophylaxis drugs [5] - The 55 million yuan raised will be used to support operational funding and accelerate the development of core research projects, ensuring the efficient rollout of a diverse and comprehensive HIV drug commercialization strategy [5]

证券日报网讯1月13日，华特达因（000915）在互动平台回答投资者提问时表示，公司褪黑素颗粒产品 曼乐静前期为意向预约，本周将在阿里和京东线上正式销售，也将陆续进入国内各地医院销售。 ...

证券日报网讯 1月13日，金河生物在互动平台回答投资者提问时表示，公司第三季度利润下滑主要原因 是化药车间安排例行检修、三季度属于行业消费淡季、六期项目投产后产量加大，公司促销优惠等原因 所致；公司11月底提高了国内和其他外销市场的金霉素售价，对第四季度的经营业绩或有一定的提升， 具体经营情况届时请关注公司披露的相关公告。 （文章来源：证券日报） ...

证券日报网讯1月13日，华特达因（000915）在互动平台回答投资者提问时表示，公司褪黑素颗粒产品 曼乐静本周即可在阿里和京东线上根据医生处方购买，后续将陆续进入国内各地医院销售。 ...

格隆汇1月13日丨艾迪药业(688488.SH)公布2026年度以简易程序向特定对象发行A股股票预案，本次发 行募集资金总额不超过（含）18,500.00万元，符合以简易程序向特定对象发行股票的募集资金总额不超 过人民币三亿元且不超过最近一年末净资产百分之二十的规定；扣除发行费用后的募集资金净额将用于 以下项目：收购南大药业22.2324%股权、补充流动资金。 MACD金叉信号形成，这些股涨势不错！ ...

2026年1月13日，山西仟源医药集团股份有限公司（以下简称"仟源医药"）发布公告称，公司第五届董 事会第三十六次会议审议通过了《关于回购注销2025年限制性股票激励计划部分限制性股票的议案》。 因2名激励对象离职不再具备激励资格，公司拟回购注销其已获授但尚未解除限售的限制性股票合计 5.00万股，回购价格为授予价格5.6元/股并支付银行同期定期存款利息，资金来源为公司自有资金。 回购背景及原因 据公告披露，仟源医药于2025年实施了2025年限制性股票激励计划（以下简称"本次激励计划"）。根据 《激励计划》相关规定，"激励对象离职的，包括主动辞职、合同到期且因个人原因不再续约、因个人 过错被公司解聘等，自离职之日起，激励对象已解除限售的限制性股票不作处理，已获授但尚未解除限 售的限制性股票不得解除限售，由公司按授予价格回购注销，并支付银行同期定期存款利息。" 此次涉及回购注销的2名激励对象因离职已不具备激励对象资格，因此公司依据《激励计划》启动回购 注销程序，拟回购注销其持有的尚未解除限售的限制性股票。 回购具体情况 回购数量 根据《激励计划》及董事会决议，本次回购价格为授予价格5.6元/股，并将按银行同期 ...

针对业绩变动的原因，亨迪药业表示，由于主产品布洛芬原料药及部分特色原料药产品市场竞争加剧， 毛利率下降。此外，现金管理利息收入因利率下降减少。 （文章来源：北京商报） 北京商报讯1月13日晚间，亨迪药业（301211）发布2025年度业绩预告显示，公司预计2025年归属净利 润为3100万元至3900万元，同比下降57.4%至66.14%。 ...

每经讯，2026年1月13日，北交所上市公司新赣江（920367，收盘价：30.55元）登上龙虎榜，交易方式是连续竞价，披露原因是 当日收盘价涨幅达到30.00%，成交数量896.48万股，成交金额2.71亿元。买一席位为国泰海通证券股份有限公司上海江苏路营业 部，买入1326.18万元；卖一席位为天府证券有限责任公司上海崂山路证券营业部，卖出947.05万元。 | | 2026-01-13新贛江 (920367) 龙虎榜 | | | | --- | --- | --- | --- | | 序号 | 交易营业部名称 | 买入金额(元) | 卖出金额(元) | | नेट ग | 国泰海通证券股份有限公司上海江苏路营业部 | 13261755 | 1869195.4 | | 买2 | 方正证券股份有限公司长沙黄兴中路证券营业部 | 11422645 | 198750 | | 址3 | 上海证券有限责任公司宁波北仑新大路证券营业部 | 7412897.65 | 0 | | ग्रेट प | 东亚前海证券有限责任公司深圳分公司 | 6826601.35 | 0 | | ન્નેર | 东莞证券股份有限公司大连星海 ...

证券之星消息，1月13日化学制药板块较上一交易日上涨0.56%，新赣江领涨。当日上证指数报收于 4138.76，下跌0.64%。深证成指报收于14169.4，下跌1.37%。化学制药板块个股涨跌见下表： 从资金流向上来看，当日化学制药板块主力资金净流入9.29亿元，游资资金净流出2643.99万元，散户资 金净流出9.03亿元。化学制药板块个股资金流向见下表： | 代码 | 名称 | 主力净流入 (元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300267 | 尔康制药 | 2.40 Z | 14.60% | -1.23 乙 | -7.49% | -1.17亿 | -7.11% | | 920367 | 新赣江 | 1.89亿 | 69.87% | 1354.67万 | 5.00% | -- | i | | 300723 | 一品红 | 1.81亿 | 9.69% | -2949.84万 | -1.58% | -1.51 Z | -8.11% | ...

Core Viewpoint - The article discusses the legal proceedings against Guangji Pharmaceutical due to financial reporting irregularities, which have led to investor losses and the opportunity for affected investors to seek compensation through legal channels [1][2][3]. Group 1: Legal Proceedings - A new batch of cases has been submitted to the court by the Liu Peng lawyer team from Shanghai Huzhi Law Firm, currently gathering affected investors [1][2]. - The case was initiated after Guangji Pharmaceutical received an administrative penalty decision from the Hubei regulatory authority on July 22, indicating issues with the company's financial reports [1][2]. Group 2: Financial Reporting Irregularities - Guangji Pharmaceutical's subsidiary, Hubei Guangji Pharmaceutical Jikang, reported inflated revenues by using the gross method instead of the net method for revenue recognition, leading to overstatements of 45.60 million yuan, 136.86 million yuan, and 138.20 million yuan for the first quarter, half-year, and third quarter of 2022, respectively, which accounted for 25.49%, 26.68%, and 20.49% of the reported revenues for those periods [3]. - The company issued a correction announcement in April 2023, acknowledging the accounting errors for the first three quarters of 2022, which were deemed violations of the Securities Law by the Hubei Securities Regulatory Bureau [2][3]. Group 3: Compensation Eligibility - Investors who purchased shares between March 25, 2022, and April 20, 2023, and sold or held them after April 21, 2023, at a loss are eligible to participate in the compensation claims, with a deadline for claims set for April 20, 2026 [3].